Duration of response to intramuscular versus low dose intradermal hepatitis B booster immunization.
OBJECTIVE
To determine the duration of the immune response to plasma-derived hepatitis B vaccine among healthcare workers responding to booster doses of intradermal (ID) or intramuscular (IM) vaccine in 1986 and those with protective levels of antibody to hepatitis B surface antigen (anti-HBs) in 1986 without booster vaccine. Both groups received a primary hepatitis B vaccine series 24 to 36 months earlier.


METHODS
Cross-sectional follow-up study two years later of an inception cohort defined in 1986.


METHODS
An academically affiliated metropolitan county hospital.


METHODS
Group 1: Hospital employees responding to booster doses of hepatitis B vaccine given ID or IM in 1986 due to low anti-HBs levels. Forty-one (82%) of 50 eligible persons were evaluated. Group 2: Persons not receiving booster vaccine in 1986 due to protective levels of anti-HBs. A random sample of 95 persons was drawn from a pool of 152 participants with protective levels in 1986. Sixty-five (68%) of 95 contacted persons were restudied.


RESULTS
In 1988, 14 (64%) of 22 previous ID responders had anti-HBs levels greater than or equal to 10 milli-international units (mIU)/mL, compared with 17 (89%) of 19 IM responders (p = .055). The 1988 geometric mean titer of IM recipients was 66.4 +/- 4.5 mIU/mL and of ID recipients was 20.7 +/- 7.4 (p = .04). None of 65 Group 2 subjects' anti-HBs titers dropped below 10 mIU/mL by 1988.


CONCLUSIONS
Plasma-derived hepatitis B vaccine recipients with anti-HBs levels greater than or equal to 10 mIU/mL at 24 to 36 months after primary immunization are likely to maintain these levels two years later. The diminished durability of the antibody response together with the increased rate of local side effects associated with the ID injection route may limit its applicability as an alternative to using IM booster doses of hepatitis B vaccine.
McKinney
W P
WP
Division of General Internal Medicine, Medical College of Wisconsin, Milwaukee.
Russler
S K
SK
Horowitz
M M
MM
Battiola
R J
RJ
Lee
M B
MB
D005500:Follow-Up Studies; D006509:Hepatitis B / Q000453:epidemiology / Q000517:prevention & control*; D017325:Hepatitis B Vaccines; D006801:Humans; D007117:Immunization, Secondary; D007271:Injections, Intradermal; D007273:Injections, Intramuscular; D009784:Occupational Diseases / Q000453:epidemiology / Q000517:prevention & control*; D010564:Personnel, Hospital; D013997:Time Factors; D014761:Viral Hepatitis Vaccines / Q000008:administration & dosage*
D017325:Hepatitis B Vaccines; D014761:Viral Hepatitis Vaccines